These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
174 related items for PubMed ID: 9486581
21. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II. Kahán Z, Sun B, Schally AV, Arencibia JM, Cai RZ, Groot K, Halmos G. Cancer; 2000 Mar 15; 88(6):1384-92. PubMed ID: 10717621 [Abstract] [Full Text] [Related]
22. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice. Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P, Busto R, Halmos G. J Clin Endocrinol Metab; 2001 May 15; 86(5):2144-52. PubMed ID: 11344219 [Abstract] [Full Text] [Related]
23. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. Pinski J, Halmos G, Schally AV. Cancer Lett; 1993 Jul 30; 71(1-3):189-96. PubMed ID: 8103419 [Abstract] [Full Text] [Related]
24. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL, Varga JL. Proc Natl Acad Sci U S A; 2003 Dec 23; 100(26):15836-41. PubMed ID: 14660794 [Abstract] [Full Text] [Related]
25. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT. Cancer Res; 1992 May 01; 52(9):2538-44. PubMed ID: 1568223 [Abstract] [Full Text] [Related]
27. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix. Halmos G, Schally AV, Kahan Z. Int J Oncol; 2000 Aug 01; 17(2):367-73. PubMed ID: 10891548 [Abstract] [Full Text] [Related]
29. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095. Miyazaki M, Lamharzi N, Schally AV, Halmos G, Szepeshazi K, Groot K, Cai RZ. Eur J Cancer; 1998 Apr 01; 34(5):710-7. PubMed ID: 9713279 [Abstract] [Full Text] [Related]
30. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV. Breast Cancer Res Treat; 1992 Apr 01; 21(3):181-92. PubMed ID: 1355375 [Abstract] [Full Text] [Related]
37. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II. Szepeshazi K, Schally AV, Rick FG, Block NL, Vidaurre I, Halmos G, Szalontay L. Anticancer Drugs; 2012 Oct 01; 23(9):906-13. PubMed ID: 22926257 [Abstract] [Full Text] [Related]
38. Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP. Qin Y, Ertl T, Cai RZ, Horvàth JE, Groot K, Schally AV. Int J Cancer; 1995 Oct 09; 63(2):257-62. PubMed ID: 7591214 [Abstract] [Full Text] [Related]
39. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095. Halmos G, Schally AV. Proc Natl Acad Sci U S A; 1997 Feb 04; 94(3):956-60. PubMed ID: 9023364 [Abstract] [Full Text] [Related]